Maternal mRNA COVID-19 vaccination shields infants for six months

Women who receive an mRNA-based COVID-19 vaccination or booster during pregnancy can provide their infants with strong protection against symptomatic COVID-19 infection for at least six months after birth, according to a study from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

Addressing industry challenges with personalized eCOA solutions

eCOA technology can help to improve the patient experience. Credit: fizkes via Shutterstock. Electronic clinical outcome assessment (eCOA) has become an essential tool for capturing

August 9, 2024

Breaking through new research barriers with iPSC technology

In this interview, we speak to Keith Olson and Coby Carlson from Fujifilm Cellular Dynamics about their iPSC technology.

February 15, 2024

Eiger ends PhIII hepatitis delta trial over safety concerns — and the search for treatment partner

Eiger BioPharmaceuticals is ending a Phase III trial investigating its treatment in liver infections caused by the hepatitis D virus over safety concerns, just a

September 14, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.